Your session is about to expire
← Back to Search
Cisplatin + Radiation for Head and Neck Cancer
Study Summary
This trial will study the standard of care radiation therapy for squamous cell carcinoma of the head and neck, with the addition of either weekly or every 3-week cisplatin. The study will look at the relationship between the cisplatin toxicity and the level of reactive oxygen species generated by the drug.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2012 Phase 3 trial • 256 Patients • NCT01005680Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am HIV-positive with uncontrolled HIV.I recently underwent chemotherapy or radiotherapy.I agree to use effective birth control methods.I had head or neck cancer before and can handle the full dose of radiation and chemotherapy.I have not received chemotherapy for my advanced head or neck cancer.My cancer has spread from its original location.My disease can be measured according to my treatment group's rules.I have not had certain types of cancer before.I do not have any uncontrolled illnesses.I agree to use birth control during the study.My cancer is considered high-risk based on its characteristics.I am 18 years old or older.My cancer has not spread to distant parts of my body.I have been diagnosed with squamous cell carcinoma in my head or neck.I can take care of myself and am up and about more than half of my waking hours.My organ and bone marrow functions are normal.I have severe hearing loss.
- Group 1: Every 3 Weeks Cisplatin + XRT
- Group 2: Weekly Cisplatin + XRT
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the upper limit on enrolment in this clinical trial?
"Indeed, the information accessed from clinicaltrials.gov supports that this research project is currently recruiting patient volunteers. This trial was initially published on April 11th 2017 and has recently been updated on November 17th 2021. A total of 80 participants are required for a single site evaluation."
Is the enrollment period still open for participation in this trial?
"Affirmative. According to clinicaltrials.gov, this medical experiment was first listed on 4/11/2017 and is presently seeking 80 volunteers from a single location. The information was most recently updated on 11/17/2021."
Have other experiments explored the effects of Cisplatin?
"Presently, 688 clinical trials are underway exploring the benefits of Cisplatin. Of these ongoing investigations, 274 are in Phase 3. Despite being based mainly in Shanghai, there exists 43211 sites conducting research on this treatment worldwide."
Has the Food and Drug Administration sanctioned Cisplatin for therapeutic use?
"There is limited evidence that demonstrates Cisplatin's safety, hence it was assigned a rating of 2."
In what ways does Cisplatin generally benefit patients?
"Often used to treat ovarian cancer, cisplatin can also be utilised for advanced testicular cancers that are unresponsive to conventional treatments as well as various other medical conditions."
Share this study with friends
Copy Link
Messenger